NCT01676519已完成不适用
Impact of Critical Limb Ischemia on Long Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 764
- 试验地点
- 1
- 主要终点
- cardiac mortality rate
研究概览
简要总结
Prospective cohort study of consecutive diabetic patients undergoing percutaneous coronary intervention (PCI) in whom development of critical limb ischemia was prospectively assessed by a dedicated diabetic foot clinic. Cardiac mortality at 4-year follow-up was the primary endpoint of the study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diabetes mellitus
- •need for coronary revascularization
- •age > 18 years
排除标准
- •clinical contraindications to prolonged double antiplatelet therapy
- •life expectancy < 1 year
- •lack of consent
结局指标
主要结局
cardiac mortality rate
时间窗: 4-year follow-up
incidence of cardiac death
次要结局
- major adverse cardiac event rate(4-year follow-up)
研究者
Leonardo Bolognese, MD
Director
Ospedale San Donato
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Impact of Diabetes Mellitus on Critical Limb Ischemia with Below the Knee DiseaseCritical limb ischemiaJPRN-UMIN000008761Sendai Kousei Hospital1,000
已完成
不适用
Evaluation of Long-term Coronary Stenting Outcomes in Diabetic Patients With or Without Optimal Glycemic ControlDiabetesCoronary Artery DiseaseNCT03338153Tehran Heart Center1,353
招募中
不适用
Prospective Cohort of Patients With Critical Limb Ischemia Undergoing RevascularizationCritical Limb IschemiaNCT04312451Fondation Hôpital Saint-Joseph300
已完成
不适用
Diabetes Control and Complications Trial (DCCT)Type 1 Diabetes MellitusNCT00360815National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1,441
进行中（未招募）
不适用
Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus GlobalDiabetesAcute Coronary SyndromeCoronary Artery DiseaseNCT04236609Concept Medical Inc.3,050